Log In
Print this Print this

Namenda XR, memantine

  Manage Alerts
Collapse Summary General Information
Company Merz GmbH & Co. KGaA
DescriptionOnce-daily extended release formulation of memantine
Molecular Target
Mechanism of ActionNMDA receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat moderate to severe Alzheimer's disease (AD)
Regulatory Designation
Partner Adamas Pharmaceuticals Inc.; Allergan plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today